The interleukin-10 levels as a potential indicator of positive response to interferon beta treatment of multiple sclerosis patients

This publication has 13 references indexed in Scilit:

• The effects of interferon‐β on interleukin‐10 in multiple sclerosis patients
  European Journal of Neurology, 2005
• Beneficial effect of interferon-β 1b treatment in patients with relapsing–remitting multiple sclerosis is associated with an increase in serum levels of soluble HLA-I molecules during the first 3 months of therapy
  Journal of Neuroimmunology, 2004
• Disease modifying therapies in multiple sclerosis: Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines [RETIRED]
  Neurology, 2002
• Interferon‐β therapy for multiple sclerosis induces reciprocal changes in interleukin‐12 and interleukin‐10 production
  Annals of Neurology, 2001
• Prognostic Value of Soluble Tumor Necrosis Factor Receptors 1 and 2 in Multiple Sclerosis Patients Treated with Interferon Beta-1b
  European Neurology, 2001
• Interferon-β in multiple sclerosis: altering the balance of interleukin-12 and interleukin-10?
  Current Opinion in Neurology, 2001
• Contrasting responses to interferon β-1b treatment in relapsing-remitting multiple sclerosis: Does baseline interleukin-12p35 messenger RNA predict the efficacy of treatment?
  Annals of Neurology, 2000
• Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis
  Annals of Neurology, 1999
• Interferon (IFN)-β treatment enhances CD95 and interleukin 10 expression but reduces interferon-γ producing T cells in MS patients
  Journal of Neuroimmunology, 1999
• New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
  Annals of Neurology, 1983